TRK Fusion + Cancers – Salisbury, MD
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This activity will cover the treatment and management of patients with non-small cell lung cancer (NSCLC).
This activity will cover the treatment and management of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).